However, the percentage decrements in AGAT activity were significantly greater in Schedule B patients who experienced grade 3 or 4 thrombocytopenia compared to those who did not experience severe platelet toxicity (mean percentage AGAT inactivation, 90.3±5.5 vs 72.5±16.1%, P<0.045). The gene discussed is GATM; the disease is Thrombocytopenia.